Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Ciric To

3PUBLICATIONS

36CO-AUTHORS

Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (3)

Sort by Publication Date:

|May 09, 2022

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.

Tyler S Beyett, Ciric To, David E Heppner

|Apr 15, 2022

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.

Ciric To, Tyler S Beyett, Jaebong Jang

|Sep 13, 2021

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancer.

Pınar Özden Eser, Raymond M Paranal, Jieun Son

Pageof 1

Frequent Collaborators

3 joint publications

Pasi A Jänne

2 joint publications

David E Heppner

2 joint publications

Nathanael S Gray

2 joint publications

David A Scott

2 joint publications

Tyler S Beyett

2 joint publications

Michael J Eck

2 joint publications

Prafulla C Gokhale

1 joint publications

Jieun Son

1 joint publications

Jeffrey J Okoro

1 joint publications

Kshiti H Dholakia

Frequent Collaborators

3 joint publications

Pasi A Jänne

2 joint publications

David E Heppner

2 joint publications

Nathanael S Gray

2 joint publications

David A Scott

Top Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on : May 20, 2020

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

See more related videos

Top Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on : May 20, 2020

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

See more related videos